Title: microRNA Expression Abnormalities of Pancreatic, Endocrine, and Acinar Tumors
Patent Number: 7,670,840
Filed: Jan. 3, 2007 PCT Filed: Jan. 3, 2007
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent's abstract states, "provides novel methods and compositions for the diagnosis, prognosis, and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agents."
Title: Inhibition of Brain Enzymes Involved in Cerebral Amyloid Angiopathy and Macular Degeneration
Application Number: 20100047336
Filed: Aug. 17, 2009
Lead Inventor: Wolff Kirsch, Loma Linda University Medical Center
The patent application, its abstract states, claims "a method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal [by] administering compositions containing siRNA to heme oxygenase-1 or heme oxygenase-2, a matrix metalloproteinase inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient."
Title: Method for Detecting Nucleic Acids
Application Number: 20100047784
Filed: June 29, 2007 PCT Filed: June 29, 2007
Lead Inventor: Gilad Shlomit, Rosetta Genomics
The patent application, its abstract states, claims "methods and compositions for detecting, amplifying, and labeling targeted nucleic acids, including microRNAs."
Title: Nucleic Acid Compounds for Inhibiting VEGF Family Gene Expression and Uses Thereof
Application Number: 20100047909
Filed: Feb. 28, 2008 PCT Filed: Feb. 28, 2008
Lead Inventor: Steven Quay, MDRNA
The invention, the patent application's abstract states, comprises "meroduplex ribonucleic acid molecules capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease."
Title: siRNA Targeting Tumor Protein 53
Application Number: 20100048425
Filed: Sept. 18, 2009
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."
Title: Stable and Long-Lasting siRNA Expression Vectors and the Applications Thereof
Application Number: 20100048670
Filed: Feb. 14, 2006 PCT Filed: Feb. 14, 2006
Lead Inventor: Denis Biard, Commissariat a l'Energie Atomique
"The invention relates to a siRNA expression vector that can inhibit or eliminate the expression of a target gene in a mammalian cell," the patent application's abstract states. "The invention also relates to the applications of one such expression vector."
Title: Compositions for Transfection of Oligonucleotides Active for Gene Silencing and Their Biological and [Therapeutic] Applications
Application Number: 20100048672
Filed: April 5, 2007 PCT Filed: April 5, 2007
Lead Inventor: Patrick Neuberg, Polyplus Transfection
"The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula," the patent application's abstract states. "The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo. The invention [also] relates to compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies."
Title: Role of miRNA in T Cell Leukemia
Application Number: 20100048674
Filed: June 8, 2009
Lead Inventor: Chang-Zheng Chen, Stanford University
"The ability of miR-181a to support active signaling between Notch and pre-TCR pathways by coordinately dampening negative regulators of these pathways allows the use of miR-181a as a therapeutic target for T-ALL," the patent application's abstract states.
Title: miRNA Triplex Formations for the Down-Regulation of Viral Replication
Application Number: 20100048675
Filed: July 30, 2009
Inventor: Omar Bagasra, Claflin University
"As discovered herein, using miRNAs having high homology with both HIV-1 and a co-infecting virus such as HHV-6, HHV-7, or GVB-C, one can inhibit viral replication, more particularly HIV-1 replication, using such mutually homologous miRNAs that give rise to the creation of stable triplex formations effective in the down-regulation and/or inhibition of viral replication," the patent application's abstract states.
Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Acute Myeloid Leukemia
Application Number: 20100048681
Filed: Jan. 29, 2008 PCT Filed: Jan. 29, 2008
Inventor: Carlo Croce, Ohio State University
The invention comprises "novel methods and compositions for the diagnosis, prognosis, and treatment of acute myeloid leukemia," the patent application's abstract states. "The invention also provides methods of identifying anti-AML agents."
Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules
Application Number: 20100048888
Filed: Oct. 17, 2007 PCT Filed: Oct. 17, 2007
Lead Inventor: Tongqian Chen, Merck
The invention, the patent application's abstract states, "relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism.
"Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules, such as … dsRNA … and small nucleic acid molecules, such as short interfering nucleic acids… to relevant cells and/or tissues, such as in a subject or organism," the abstract adds. "Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism."